Social media

There are many considerations that set oncology biosimilar development apart from that of novel biologics. Read ICON’s article in Drug Discovery & Development magazine to better prepare for challenges such as developing ...

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This whitepaper explores how regulatory teams can prepare unified materials that meet the requirements of...

Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in #childhoodcancer and other #pediatric diseases. https://ow.ly/VXSx50WOVcN #ChildhoodCancer #Childh...

If your company requires urgent rescue assistance – consider changing CRO. Impossible? Read the full story and learn how the ICON and Sponsor teams had to rapidly prepare for data cuts, while simultaneously transitionin...

Biotechs and pharma companies in Asia Pacific face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is p...

Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports: • Stronger regulatory alignment • Patient-centered outcomes • Better trial efficiency 📅 Oct 7 | 11am EDT | https://ow.ly/61yJ50...

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia. Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect...

Join ICON at the World CB & CDx Summit, 22–25 September in Boston. With deep scientific expertise, cutting-edge technologies, and seamless clinical trial integration, we translate exploratory research into real-world a...

What does it take to lead with both heart and science? In the second installment of our employee spotlight series #BehindBiotech, we meet Dr. Mark Sorrentino - Vice President and Head of ICON’s Centre for Pediatric Clin...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Faster access to life-saving therapies is within reach. Global regulators are working together to speed approvals for oncology and rare disease treatments—but navigating these pathways takes foresight and expertise. Ou...

At #DPHARM2025 on 17 September at 3:40 PM, Faith Gabel will lead a pivotal session on evolving site networks beyond transactional execution toward delivering lasting value. Her insights will help clinical research profe...